Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives

被引：42
|
作者：
Herbreteau, Guillaume [1 ]
Vallee, Audrey [1 ]
Charpentier, Sandrine [1 ]
Normanno, Nicola [2 ]
Hofman, Paul [3 ,4 ,5 ]
Denis, Marc G. [1 ]
机构：
[1] Nantes Univ Hosp, Dept Biochem, 9 Quai Moncousu, F-44093 Nantes, France
[2] Fdn G Pascale, IRCCS, Ist Nazl Tumori, Cell Biol & Biotherapy Unit, Naples, Italy
[3] Univ Cote Azur, CHU Nice, CNRS 7284, INSERM,Lab Clin & Expt Pathol,U1081, Nice, France
[4] Pasteur Hosp, FHU OncoAge, Nice, France
[5] Pasteur Hosp, Hosp Integrated Biobank BB 0033 00025, Nice, France
来源：
JOURNAL OF THORACIC DISEASE | 2019年 / 11卷
关键词：
Circulating tumor DNA (ctDNA); non-small cell lung cancer (NSCLC); EGFR mutation; ALK translocation; tumor mutation burden (TMB); minimal residual disease (MRD); MOLECULAR TESTING GUIDELINE; T790M RESISTANCE MUTATION; OF-AMERICAN-PATHOLOGISTS; EGFR MUTATION; LIQUID BIOPSY; ACQUIRED-RESISTANCE; ADENOCARCINOMA PATIENTS; CEREBROSPINAL-FLUID; ALK REARRANGEMENT; BRAF MUTATION;
D O I：
10.21037/jtd.2018.12.18
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Major advances in the treatment of non-small cell lung cancer (NSCLC) patients have been obtained during the last decade. Molecular testing of tumor samples is therefore mandatory in routine clinical practice. Tumor DNA is also present as cell-free molecules in blood, which is therefore a very useful and convenient source of tumor DNA. In this review, we discuss pre-analytical and analytical aspects of circulating tumor DNA (ctDNA) analysis. We also describe the use of ctDNA analysis in routine clinical practice, and discuss the potential use of ctDNA monitoring both to identify minimal residual disease and as a potential tool to early identify patients' response to treatment.
引用
收藏
页码：S113 / S126
页数：14
相关论文
共 50 条
  • [1] Possible application of circulating free tumor DNA in non-small cell lung cancer patients
    Karachaliou, Niki
    Sosa, Aaron E.
    Angel Molina, Miguel
    Centelles Ruiz, Margarita
    Rosell, Rafael
    JOURNAL OF THORACIC DISEASE, 2017, 9 : S1364 - S1372
  • [2] Clinical Significance of Circulating Tumor Cells and Free DNA in Non-small Cell Lung Cancer
    Isobe, Kazutoshi
    Hata, Yoshinobu
    Kobayashi, Kunihiko
    Hirota, Nao
    Sato, Keita
    Sano, Go
    Sugino, Keishi
    Sakamoto, Susumu
    Takai, Yujiro
    Shibuya, Kazutoshi
    Takagi, Keigo
    Homma, Sakae
    ANTICANCER RESEARCH, 2012, 32 (08) : 3339 - 3344
  • [3] Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer
    Zhang, Yuting
    Zheng, Hongmei
    Zhan, Yuting
    Long, Mengping
    Liu, Sile
    Lu, Junmi
    Zang, Hongjing
    Fan, Songqing
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (12): : 2377 - 2386
  • [4] Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
    Yang, Jialiang
    Hui, Yan
    Zhang, Yanxiang
    Zhang, Minghui
    Ji, Binbin
    Tian, Geng
    Guo, Yangqiang
    Tang, Min
    Li, Lianxing
    Guo, Bella
    Ma, Tonghui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer
    Liu, Xin
    Yang, Yue
    Ren, Zihan
    Cui, Youbin
    Lu, Tianyu
    Wang, Rui
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [6] The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Grinberg, R.
    Roisman, L.
    Geva, S.
    Lefterova, M.
    Quinn, K.
    Gutman, L. Soussan
    Dvir, A.
    Yair, R.
    Twito, T.
    Lanman, R.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S925 - S926
  • [7] The influence of circulating tumor DNA analysis on response to immunotherapy in non-small cell lung cancer (NSCLC)
    Grinberg, R.
    Roisman, L. C.
    Geva, S.
    Soussan-Gutman, L.
    Dvir, A.
    Yair, R.
    Twito, T.
    Larman, R.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S35 - S36
  • [8] KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
    Garzon, Monica
    Villatoro, Sergi
    Teixido, Cristina
    Mayo, Clara
    Martinez, Alejandro
    Llanos Gil, Maria de Los
    Viteri, Santiago
    Morales-Espinosa, Daniela
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 511 - 516
  • [9] Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
    Nie, Kun
    Jia, Yujie
    Zhang, Xuezhu
    TUMOR BIOLOGY, 2015, 36 (01) : 7 - 19
  • [10] Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
    Rauthan, A.
    Prabhash, K.
    Rohatgi, N.
    Thirumalairaj, R.
    Agarwal, A.
    Limaye, S.
    Batra, U.
    Raizada, N.
    Patil, P.
    Palanki, S. Dattatreya
    Sirohi, B.
    Dhar, A.
    Mukherjee, A. K.
    Joshi, N.
    Olsen, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1538
12345